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Role ofthrombin after vascular Injury. Thrombus forma-
tion plays a central role in the healing process that follows
acute vascular injury . Thrombin is the critical enzyme in
early thrombus formation, cleaving fibrinopeptidt :s A and B
from fibrinogen to yield insoluble fibrin, which effectively
serves as the foundation of the evolving thrombus . Both free
and fibrin-bound thrombin are able to convert fibrinogen to
fibrin, allowing propagation of thrombus at the site of injury .
Thrombin activates Factor XIII, which can then cross-link
fibrin, increasing its mechanical stability and resistance to
lysis. Circulating platelets are recruited to the site of injury,
adhere to thrombogenic substances such as subendothelial
matrix proteins and contribute to clot formation. Thrombin
then aggregates the platelets, further reinforcing the evolving
thrombus. In addition to these prothrombotic effects, throm-
bin initiates a series of reactions that activate endogenous
anticoagulant systems . Thrombin generated at the site of
injury binds to thrombomodulin, an endothelial surface
membrane protein, initiating activation of protein C, which
in turn (in the presence of protein S) inactivates Factors Va
and Villa . Thrombin stimulates successive release of both
tissue plasminogen activator (t-PA) and plasminogen activa-
tor inhibitor type I from endothelial cells, thus initiating
endogeneous thrombolysis through plasmin generation from
plasminogen by t-PA with subsequent modulation through
plasminogen activator inhibitor type 1 (1,2) . Thrombin there-
fore plays a pivotal role in maintaining the intricate balance
of initial prothrombotic reparative events and subsequent
endogenous anticoagulant and thrombolytic pathways .
The importance of thrombin lies not just in acute throm-
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bus formation after vascular injury such as that caused by
angioplasty or plaque rupture
. Thrombin must also be con-
sidered an effector molecule . Inducible receptors for throm-
bin have been demonstrated on endothelial and vascular
smooth muscle cells (3) . The addition of thrombin in physi-
ologic concentration to bovine aortic endothelial cells in
culture significantly reduces endothelial cell proliferation
compared with controls . Vascular smooth muscle cell pro-
liferation in cell culture is increased in response to addition
of thrombin to the culture medium. Smooth muscle matrix
production is altered by thrombin in this setting, with an
increase in total protein and collagen content (4) .
Human umbilical vein endothelial cells in culture release
a platelet-derived growth factorlike (PDGFc) molecule in
response to physiologically relevant concentrations of
thrombin, mediated by intracellular conversion of PDGFc
from an inactive to an active form (5) . Cultured human
microvascular renal endothelial cells exhibited increased
levels of a c-sis gene product for platelet-derived growth
factor in response to thrombin exposure, with peak activity
4 h after exposure to thrombin . Receptor activation results in
an increase in messenger ribonucleic acid for the c-sis gene,
mediated by activation of protein kinase C (6) . Neither of
these effects of thrombin on endothelial sells requires the
proteolytic activity of the enzyme .
Human alpha thrombin has been shown to be a potent
mitogen for rat aortic smooth muscle cells in culture . How-
ever, in this model the stimulus for proliferation was depen-
dent on a functional proteolytic site (7) . Thus, thrombin has
direct effects on cell proliferation and influences the cellular
synthetic mechanisms responsible for matrix protein and
collagen production (4). Thrombin-mediated platelet-derived
growth factor synthesis by endothelial cells further demon-
strates the potential impact of this compound on the relative
proliferative response of endothelial and smooth muscle
cells after an injury such as that created by balloon angio-
plasty .
Thrombin has direct effects on white blood cells as well .
lnterleukin-1 release from macrophages can be induced by
thrombin (8) . This cytokine stimulates smooth muscle cell
proliferation, and also induces endothelial expression of
leukocyte adhesion molecules (9,10). Preliminary data from
our labotatory suggest that thrombin can potentiate neutro-
phil degranulation in response to known agonists such as
leukotriene B4 in vitro (Deutsch E, unpublished observa-
tions). Thrombin can thus enhance recruitment of leuko-
cytes to the site of injury and may contribute to local release
of leukotrienes and other vasoactive effectois and proteases
such as elastase from adherent neutrophils .
Iiirudins versus heparlns as anticoagulants. Hirudin is a
selectOe thrombin inhibitor that binds directly, tightly and
rapidly to thrombin in a stoichiometric fashion
. This 65-
amino acid polypeptide was isolated from the leech Hirudo
medicina"is more than 30 years ago (I 1)
. Subsequent de-
velopment of hirudin derivatives include recombinant
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desulfato-hirudin (r-hirudin, CGP 39393) and a 20-amino acid
synthetic peptide (hirulog) that binds both to the catalytic
site of thrombin and to in exosite required for thrombin
binding to fibrinogen and thrombospondin
(12). Hirudins
offer several potential advantages as anticoagulants when
compared with heparin
. Hirudins neutralize thrombin di-
rectly without the need for an intermediary molecule such as
antithrombin ui . Although heparins are inactivated by anti-
heparin proteins such as platelet factor 4 (13), no similar
situation is observed with hirudins . Both recombinant hiru-
din and hirulog can inhibit thrombin-mediated platelet acti-
vation and generation of fibrin through cleavage of fibrino-
peptides A and B from fibrinogen in vitro and in in vivo
models of thrombosis (1l). Although thrombin bound to
fibrin is resistant to inactivation by heparin-antithrombin III
complex, inhibition of clot-bound thrombin is effectively
achieved with recombinant hirudin (14). Thrombin-mediated
platelet activation is not influenced by heparin (13) . How-
ever, hirudin does inhibit thrombin-induced platelet activa-
tion (11) . These observations are relevant to clinical condi-
tions such as rethrombosis after successful coronary
thrombolysis or propagation of venous thrombi, conditions
where fibrin-bound thrombin in an evolving clot is still able
to convert fibrinogen to fibrin and to activate circulating
platelets in the face of ongoing anticoagulation with heparin .
Preesut study. In this issue of the Journal, Verstraete et
al. (15) describe the biologic effects and pharmacokinetics of
recombinant desulfato-hirudin (COP 39393) when adminis-
tered subcutaneously and intravenously in normal human
volunteers . This compound differs from the natural leech
hirudin only in the absence of a sulfato group on tyrosine 63 .
The effects of single and multiple sequential doses of r-
hirudin on coagulation variables are presented, with parallel
measurements of plasma drug concentrations . Dose-
dependent prolongation of thrombin time and activated
partial thromboplastin time are observed . The magnitude of
activated partial thr mboplastin time prolongation ranged
from 1 .5 to 2 .5 times baseline in the doses employed, a level
of anticoagulation useful in clinical practice, A peak effect on
activated partial thromboplastin time was sustained for 3 to
6 h after subcutaneous administration. A linear relation was
observed between the extent of activated partial thrombo-
plastin time prolongation and plasma hirudin levels . There
was no evidence for cumulative effects on the magnitude or
time course of anticoagulation in volunteers who received
multiple doses at intervals of every 8 or 12 h . No increase in
bleeding time was observed, a not unexpected finding,
because hirudins have no direct effect on platelets and may
not impair the establishment of primary hemostasis. These
and other studies (16-19) document the in vivo effects of
hirudins and constitute careful pharmacologic studies that
define the appropriate doses for clinical use .
Eitpethue t a studies of hh udin, Hirudins have been
shown to be effective in reducing the extent of vascular
thrombosis in a number of animal models. Experimental
venous thrombosis in the : rat (20.21) and rabbit (22,23) was
JACC Vol. 22, No. 4
October 1993 ;1099-92
minimized or prevented by increasing systemic doses of
recombinant hirudin. The extent of thrombus formation at
the site of arterial deendothelialization after balloon angio-
plasty of the porcine carotid artery (24) or rabbit femoral
artery (25) was reduced by intravenous r-hirudin in a dose-
dependent fashion . The magnitude of both platelet and fibrin
deposition at the angioplasty site in the porcine carotid
artery was reduced by hirudin to a significantly greater
degree than by heparin (24) . Rethrombosis after balloon
arterial injury and thrombolysis was successfully inhibited
by subcutaneous hirudin in the rabbit jugular artery (25) . The
addition of hirulog to t-PA resulted in enhanced thromboly-
sis and a reduction in rethrombosis in a canine model of
coronary thrombosis (26) . Platelet and fibrin deposition at
the site of stent deployment in the porcine coronary artery
was significantly reduced by r-hirudin relative to the levels
achieved with heparin and dextran (27). R-hirudin has also
been employed as an antithrombotic agent in cardiopulmo-
nary bypass in the dog (11). Effective anticoagulation was
achieved, paralleled by preservation of platelet count and
fibrinogen levels . Hirudin also inhibits neutrophil degranu-
lation, as measured by elastase release, in a model of
simulated cardiopulmonary bypass (Colman RW, unpub-
lished observations) . Thus, hirudin inhibits the prothrom-
botic effects of free and surface-bound thrombin in experi-
mental arterial and venous thrombosis and on synthetic
surfaces .
The potential impact of r-hirudin (CGP 39393) on inhibi-
tion of the cellular proliferative responses to thrombin is
illustrated by a reduction in the magnitude of restenosis after
balloon angioplasty in the femoral arteries of atherosclerotic
rabbits (28). Animals received either a heparin bolus or an
r-hirudin bolus immediately before angioplasty . A 2-h intra-
venous infusion was continued in the r-hirudin cohort .
Activated partial thromboplastin times were prolonged to 1 .5
to 2 times control level in both treatment groups . Rabbits
receiving r-hirudin had significantly less angiographic resten-
osis at 28 days after the procedure, paralleled by a significant
reduction in the extent of lumen cross-sectional area narrow-
ing as deter-mined by planimetric analysis of histologic
sections . This study demonstrates that, in this model, throm-
bin generation at the time of angioplasty plays an important
role in triggering the cellular events responsible for the
restenosis process. Thrombin inhibition with r-hirudin sig-
nificantly reduced the magnitude of neointimal hyperplasia,
and was not accompanied by hemorrhagic complications .
Current clinical trials of hirudin . Several clinical trials of
hirudins are currently underway . A preliminary report com-
paring intravenous r-birudin (CGP 39393) with conventional
anticoagulation with heparin during coronary angioplasty
examined the incidence of adverse events in a randomized
cohort of patients (29) . In comparison with patients treated
with heparin, patients who received r-hirudin had a lower
incidence of thrombotic events after angioplasty (acute
myocardial infarction, emergency coronary artery bypass
surgery) . The relative risk of postprocedure ischemia, as
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nlvasured by ST segment changes on 24-hour Holier ambu-
latory electrocardiographic monitoring, was significantly re-
duced in the r-hirudin cohort . The investigators concluded
that hirudin was a safe and effective form of anticoagulation
during coronary angioplasty and appeared to reduce the
likelihood of recurrent thrmbotic events in the immediate
postprocedure period . R-hirudin (CGP 39393) has also been
shown to be an effective anticoagulant for prophylaxis of
thromboembolic complications in patients undergoing elec-
tive hip surgery (30) . A 10% incidence of embolic complica-
tions was observed in 24 patients treated with 15 to 20 mg of
r-hirudin subcutaneously two times daily . No increase in
periprocedural bleeding was observed in these patients, who
received the initial r-hirudin dose preoperatively. These
results compared favorably with those in control subjects
treated with conventional or low molecular weight heparin .
Hirulog has been employed as the sole anticoagulant in a
series of 45 patients undergoing diagnostic coronary angiog-
raphy (31) . Two dosing regimens of hirulog were compared
with conventional anticoagulation with a 5,000 1' heparin
intravenous bolus . Systemic anticoagulation with hirulog
was rapidly achieved . Dose-dependent increases in activated
partial thromboplastin time, prolhrombin time and activated
clotting time were observed, in a fashion similar to patients
who received heparin . The mean half-life of this effect on
activated partial thromboplastin time was 40 min . Fibrino-
peptide A generation was effectively suppressed, and there
was no evidence of major or minor hemorrhagic complica-
tions during hirulog administration in these patients . The
efficacy of hirulog as sole anticoagulant during coronary
angioplasty was further evaluated in a multicenter study of
208 patients (32) . All patients received aspirin . Four dosing
regimens were employed, achieving decremental increases
in activated clotting time . An 11% incidence of abrupt vessel
closure in the lower dose hirulog groups (median activated
clotting time 268 and 290 s) was reduced to 3% in those
patients receiving a higher dosing regimen (activated clotting
time 336 and 375 s, p = .03). Again, no hemorrhagic or
vascular complications were observed . Hirulog as a direct
thrombin inhibitor is well tolerated and in appropriate doses
may be a potent antithrombotic agent for use during coro-
nary angioplasty . Hirulog has also been utilized as an
anticoagulant for preventing venous thrombosis after hip
surgery (33). A dose of 1 .0 mglkg body weight was injected
subcutaneously every 8 h for 3 days . No major bleeding was
observed in 177 patients, who were followed up for 14 days .
The effects on coagulation variables observed were similar
to those reported for CGP 39393 by Verstraete et al . (15) .
The development of antibodies to hirulog was not observed
in these patients. Thus, it appears that there is no increased
incidence of risks or complications when using r-hirudin
(COP 39393) or hirulog in lieu of heparin in all available
studies . Indeed, these preliminary studies suggest that anti-
coagulation with r-hirudin or hirulog during coronary angio-
plasty results in a reduction in abrupt vessel closure as
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compared with a to i9% inc dence in historical control
subjects (34) .
Other thrombin inhibitors . In addition to hirudins, there are
several other highly specific thrombin inhibitors under evalua-
tion, including argatroban, a reversible competitive thrombin
inhibitor (35), argidipine (36), and D-phenylalanine-L-prolyl-L-
arginyl-chloromethyl ketone (PPACK), an irreversible serine
protease inhibitor (37) . In a recent clinical trial, intravenous
argatroban was initially effective in the treatment of unstable
angina (38) . However, anginal symptoms reappeared in 9 of 43
patients, typically 4 to 8 hours after cessation of the argatroban
infusion, and may reflect renewed thrombin activity and throm-
bus formation in parallel with diminishing plasma argatroban
levels . This observation serves to highlight the contribution of
thrombus formation as a final common event in acute ischemic
syndromes, and the initial efficacy of direct thrombin inhibition
in the treatment of unstable angina .
Conclusions. Hirudin and its derivatives show great
promise as systemic anticoagulants . There would seem to be
distinct advantages over heparin, which requires the pl : .rtic-
ipation of antithrombin III and is rather ineffective in neu-
tralizing thrombin on cell surfaces . Nonetheless, hirudins,
like all global inhibitors of thrombin, have the potential to
result in unwanted hemorrhage . The application of hirudins
in clinical situations is thus tempered by the lack of an
effective antidote to rapidly terminate their action analogous
to the effect of prolamine on heparin . A number of potential
approaches to reverse the antithrombotic effect of hirudins
need to be explored further. Acetylated thrombins (which
are not prothrombotic) bind to hirudins and thus inhibit their
anticoagulant effects (39) . Recombinant Factor Vila will
generate new thrombin, which can then complex with circu-
lating hirudin (1I) . The development of monoclonal or
polyclonal antibodies to hirudins might provide a novel
approach to neutralize their anticoagulant effects .
Available experimental data suggest that systemic or
site-specific delivery of hirudin compounds in the setting of
plaque rupture or the period after angioplasty might favor-
ably influence the magnitude of long-term cellular prolifera-
tive responses (24,28) . The global inhibitory effects of hiru-
din, including thrombin action on platelets and other cells,
and blood coagulation via fibrin generation suggest that
specific thrombin inhibitors may be the next major
advance
in antithrombotic therapy .
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